Biologic effects of fenbendazole in rats and mice

A review

David Villar, Carolyn Cray, Julia Zaias, Norman H. Altman

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

This review summarizes findings from toxicologic, carcinogenic, immunologic, and metabolic studies on fenbendazole (FBZ). Currently, FBZ is used to treat or prevent pinworm outbreaks in laboratory rodents. Because antiparasitic treatments usually are not part of experimental designs, interactions from the medication on the outcomes of ongoing experiments are a concern. At therapeutic levels, FBZ does not alter the total content of cytochromes P450 but does induce certain hepatic cytochrome P450 isoforms, namely 1A1, 1A2, and 2B1. Although expressed constitutively at low or undetectable levels, these isoforms particularly are known for bioactivating a number of procarcinogens. Lifetime studies in rats have shown that FBZ is not a carcinogen but that it may behave as a tumor promoter when given after certain initiators. Unlike in other animal species, FBZ treatment-associated myelosuppression has not been reported to occur in rodents. The few currently available immunologic studies in mice, including an autoimmune model, have not shown effects on selected immune responses. However, data from other animal species suggest that the ability of B and T lymphocytes to proliferate in the secondary immune response may be suppressed during treatment with FBZ.

Original languageEnglish
Pages (from-to)8-15
Number of pages8
JournalJournal of the American Association for Laboratory Animal Science
Volume46
Issue number6
StatePublished - Nov 1 2007

Fingerprint

fenbendazole
rats
mice
cytochrome P-450
rodents
immune response
metabolic studies
carcinogens
drug therapy
B-lymphocytes
animals
T-lymphocytes
experimental design
therapeutics
liver
neoplasms

ASJC Scopus subject areas

  • Animal Science and Zoology

Cite this

Biologic effects of fenbendazole in rats and mice : A review. / Villar, David; Cray, Carolyn; Zaias, Julia; Altman, Norman H.

In: Journal of the American Association for Laboratory Animal Science, Vol. 46, No. 6, 01.11.2007, p. 8-15.

Research output: Contribution to journalArticle

@article{02e454d9dcb04e83aaa79185e58ce4e4,
title = "Biologic effects of fenbendazole in rats and mice: A review",
abstract = "This review summarizes findings from toxicologic, carcinogenic, immunologic, and metabolic studies on fenbendazole (FBZ). Currently, FBZ is used to treat or prevent pinworm outbreaks in laboratory rodents. Because antiparasitic treatments usually are not part of experimental designs, interactions from the medication on the outcomes of ongoing experiments are a concern. At therapeutic levels, FBZ does not alter the total content of cytochromes P450 but does induce certain hepatic cytochrome P450 isoforms, namely 1A1, 1A2, and 2B1. Although expressed constitutively at low or undetectable levels, these isoforms particularly are known for bioactivating a number of procarcinogens. Lifetime studies in rats have shown that FBZ is not a carcinogen but that it may behave as a tumor promoter when given after certain initiators. Unlike in other animal species, FBZ treatment-associated myelosuppression has not been reported to occur in rodents. The few currently available immunologic studies in mice, including an autoimmune model, have not shown effects on selected immune responses. However, data from other animal species suggest that the ability of B and T lymphocytes to proliferate in the secondary immune response may be suppressed during treatment with FBZ.",
author = "David Villar and Carolyn Cray and Julia Zaias and Altman, {Norman H.}",
year = "2007",
month = "11",
day = "1",
language = "English",
volume = "46",
pages = "8--15",
journal = "Journal of the American Association for Laboratory Animal Science",
issn = "1559-6109",
publisher = "American Association for Laboratory Animal Science",
number = "6",

}

TY - JOUR

T1 - Biologic effects of fenbendazole in rats and mice

T2 - A review

AU - Villar, David

AU - Cray, Carolyn

AU - Zaias, Julia

AU - Altman, Norman H.

PY - 2007/11/1

Y1 - 2007/11/1

N2 - This review summarizes findings from toxicologic, carcinogenic, immunologic, and metabolic studies on fenbendazole (FBZ). Currently, FBZ is used to treat or prevent pinworm outbreaks in laboratory rodents. Because antiparasitic treatments usually are not part of experimental designs, interactions from the medication on the outcomes of ongoing experiments are a concern. At therapeutic levels, FBZ does not alter the total content of cytochromes P450 but does induce certain hepatic cytochrome P450 isoforms, namely 1A1, 1A2, and 2B1. Although expressed constitutively at low or undetectable levels, these isoforms particularly are known for bioactivating a number of procarcinogens. Lifetime studies in rats have shown that FBZ is not a carcinogen but that it may behave as a tumor promoter when given after certain initiators. Unlike in other animal species, FBZ treatment-associated myelosuppression has not been reported to occur in rodents. The few currently available immunologic studies in mice, including an autoimmune model, have not shown effects on selected immune responses. However, data from other animal species suggest that the ability of B and T lymphocytes to proliferate in the secondary immune response may be suppressed during treatment with FBZ.

AB - This review summarizes findings from toxicologic, carcinogenic, immunologic, and metabolic studies on fenbendazole (FBZ). Currently, FBZ is used to treat or prevent pinworm outbreaks in laboratory rodents. Because antiparasitic treatments usually are not part of experimental designs, interactions from the medication on the outcomes of ongoing experiments are a concern. At therapeutic levels, FBZ does not alter the total content of cytochromes P450 but does induce certain hepatic cytochrome P450 isoforms, namely 1A1, 1A2, and 2B1. Although expressed constitutively at low or undetectable levels, these isoforms particularly are known for bioactivating a number of procarcinogens. Lifetime studies in rats have shown that FBZ is not a carcinogen but that it may behave as a tumor promoter when given after certain initiators. Unlike in other animal species, FBZ treatment-associated myelosuppression has not been reported to occur in rodents. The few currently available immunologic studies in mice, including an autoimmune model, have not shown effects on selected immune responses. However, data from other animal species suggest that the ability of B and T lymphocytes to proliferate in the secondary immune response may be suppressed during treatment with FBZ.

UR - http://www.scopus.com/inward/record.url?scp=38449084702&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38449084702&partnerID=8YFLogxK

M3 - Article

VL - 46

SP - 8

EP - 15

JO - Journal of the American Association for Laboratory Animal Science

JF - Journal of the American Association for Laboratory Animal Science

SN - 1559-6109

IS - 6

ER -